Capital Markets Day

RNS Number : 0169R
Advanced Medical Solutions Grp PLC
24 June 2015

24 June 2015

Advanced Medical Solutions Group plc

(“AMS” or the “Group”)

 

Capital Markets Day

 

Winsford, UK, 24 June 2015 – Advanced Medical Solutions Group plc (AIM: AMS.L), the surgical and advanced woundcare specialist company, will today host a Capital Markets Day for financial analysts and institutional investors from 12:30 – 16:00 GMT, in London.

 

The event, which will provide an opportunity for participants to meet some of the Group’s senior management team, will begin with a short corporate update on strategy from Chris Meredith, Chief Executive Officer, followed by a focus on LiquiBand® in the US market, a surgeon discussion led by Assistant Professor Bernhard Dauser from the Department of Surgery at St John of God Hospital, Vienna, on the benefits of LiquiBand® Fix 8®, and a session on innovation and market opportunities across the complete AMS product platform.

 

No new material information will be disclosed during the event.

 

For more information, please contact ams@consilium-comms.com or call +44 (0) 20 3709 5700.

 

– Ends –

 

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc

Chris Meredith, Chief Executive Officer

Mary Tavener, Group Finance Director

 

 

 

+44 (0) 1606 545508

Consilium Strategic Communications

Mary-Jane Elliott / Jonathan Birt / Matthew Neal / Ivar Milligan

 

+44 (0) 20 3709 5700

AMS@consilium-comms.com

 

About Advanced Medical Solutions Group plc – see www.admedsol.com 

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.

AMS’s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in 65 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Group has approximately 470 employees. For more information please see www.admedsol.com.

 


This information is provided by RNS
The company news service from the London Stock Exchange

END

MSCEAKKDADSSEFF